57 recruiting. 57 Phase 2, 15 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 57 | Recruiting 57 |
| Phase 1 | 15 | Recruiting 15 |
| Phase 3 | 3 | Recruiting 3 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-11-01 | 2026-10-27 |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis FT819 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Fate Therapeutics | 53 | 2026-07-27 | 2026-09-14 |
| A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy HRS-5965 Capsules - Primary IgA Nephropathy | Phase 2 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 380 | 2026-07-06 | 2026-07-22 |
| EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety Exaluren - Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | Phase 2 | Recruiting | Eloxx Pharmaceuticals, Inc. | 24 | 2026-06-30 | 2026-09-30 |
| A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Mosunetuzumab - Lupus, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Hoffmann-La Roche | 30 | 2026-05-25 | 2026-10-19 |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| A Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101 - IgA Nephropathy | Phase 2 | Recruiting | Jade Biosciences, Inc. | 30 | 2026-05-19 | 2026-09-25 |
| PS-002 for the Treatment of IgA Nephropathy in Adults PS-002 - Immunoglobulin A (IgA) Nephropathy | Phase 1 / Phase 2 | Recruiting | Purespring Therapeutics Limited | 32 | 2026-03-30 | 2026-09-09 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. zigakibart - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 32 | 2026-03-26 | 2026-10-21 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| A Study of SHR-2173 in Participants With Primary IgA Nephropathy SHR-2173 injection, Placebo - Primary IgA Nephropathy | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 84 | 2026-03-09 | 2026-05-13 |
| SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide - REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 24 | 2026-03-02 | 2026-04-13 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) Obecabtagene autoleucel - Lupus Nephritis | Phase 2 | Recruiting | Autolus Limited | 35 | 2026-01-16 | 2026-08-24 |
Showing 20 of 57. Sign in to see all of them.
Lupus Nephritis (26) · Glomerulonephritis, IGA (19) · Lupus Erythematosus, Systemic (14) · Autoimmune Diseases (11) · Glomerulosclerosis, Focal Segmental (7) · Glomerulonephritis, Membranous (6) · Kidney Diseases (6) · Nephrosis, Lipoid (6) · Proteinuria (6) · Glomerulonephritis (5) · Immune System Diseases (4) · Scleroderma, Systemic (4) · Macular dystrophy, corneal type 1 (3) · Nephrotic Syndrome (3)
Female Urogenital Diseases (57) · Female Urogenital Diseases and Pregnancy Complications (57) · Male Urogenital Diseases (57) · Urogenital Diseases (56) · Urologic Diseases (56) · Glomerulonephritis (51) · Kidney Diseases (51) · Immune System Diseases (48) · Autoimmune Diseases (39) · Connective Tissue Diseases (28) · Skin and Connective Tissue Diseases (28) · Lupus Erythematosus, Systemic (12) · Nephrosis (9) · Pathological Conditions, Signs and Symptoms (9)
Cyclophosphamide (5) · Mycophenolic Acid (4) · fludarabine (4) · Rituximab (3) · Cyclosporine (2) · Methylprednisolone (2) · Prednisone (2) · belimumab (2) · sparsentan (2) · telitacicept (2) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Azathioprine (1) · CTL019 chimeric antigen receptor (1) · Diphenhydramine (1)
Beijing GoBroad Hospital (3) · ADARx Pharmaceuticals, Inc. (2) · Akebia Therapeutics (2) · Haisco Pharmaceutical Group Co., Ltd. (2) · Hoffmann-La Roche (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Pharmaceuticals (2) · Alice Bertaina (1) · AstraZeneca (1) · Autolus Limited (1) · Beijing Biotech (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Bio-Thera Solutions (1) · Cabaletta Bio (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
United States (30) · China (20) · United Kingdom (10) · Spain (8) · Australia (6) · Brazil (6) · Italy (6) · Canada (4) · Poland (4) · South Korea (4) · Taiwan (4) · Argentina (3) · France (3) · Germany (3) · Mexico (3)
Alberto Ortiz Arduan (1) · Alice Bertaina, MD (1) · Anne-Els Van de Logt, M.D., PhD (1) · Arezoo Mirad (1) · Arezoo Mirad, MD (1) · Betty Diamond, M.D. (1) · Caitlin Elgarten, MD (1) · Chee Kay Cheung, MBChB PhD (1) · Chitra Hosing, MD (1) · Cijiang He (1) · David Wofsy, M.D. (1) · Desmond Yap, MD (HK) (1) · Diana Karpman (1)
PMID 33311560, PMID 36821613, PMID 37678236, PMID 38299639, PMID 38334499, PMID 38724717, PMID 39899371, PMID 40938675, PMID 41630898, PMID 42309556, PMID 42384439
2025 (3), 2018 (1), 2019 (1), 2023 (1), R01AR079124 (1)